The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease

Michael P. Duggan, Evangelos D. Katsanos, Hassan Hamandi

Open source

DOI
10.1002/jpn3.70534
Published
2026-08-13
Container
Journal of Pediatric Gastroenterology and Nutrition
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/jpn3.70534,
  title = {The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease},
  author = {Michael P. Duggan and Evangelos D. Katsanos and Hassan Hamandi},
  year = {2026},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  doi = {10.1002/jpn3.70534},
  url = {https://doi.org/10.1002/jpn3.70534}
}

RIS

TY  - JOUR
TI  - The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease
AU  - Michael P. Duggan
AU  - Evangelos D. Katsanos
AU  - Hassan Hamandi
PY  - 2026
JO  - Journal of Pediatric Gastroenterology and Nutrition
DO  - 10.1002/jpn3.70534
UR  - https://doi.org/10.1002/jpn3.70534
ER  - 

APA

Duggan, M. P., Katsanos, E. D., & Hamandi, H. (2026). The effectiveness and safety of Risankizumab in pediatric patients with medically refractory inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70534

Source records